From: James Rogers (jamesr@best.com)
Date: Fri Dec 22 2000 - 14:57:11 MST
At 01:26 PM 12/22/00 -0800, you wrote:
>I don't recall seeing any comments over the summer on this article from
>Scientific American claiming that a new drug (ALT-711) can restore
>elasticity to ageing tissue, thus improving cardiac function (demonstrated
>in mammals) and possibly providing other benefits as well.
>
>Any comments?
While I don't have any specific comments, other than ALT-711 and that
entire family of new compounds (there are others being investigated by the
same company) does look very promising and interesting in that it is
exploring a new area of potentially useful pharmaceuticals. Alteon (ALT),
the company that developed the compound, recently completed Phase IIa
trials and while the official results aren't out yet, rumor has it (take it
for what its worth) that they are looking good. They just received $6-7M
in funding to accelerate and expand trials of ALT-711.
Of course, the only reason I know any of this is that I bought a bunch of
their stock over a year ago at less than a dollar per share. They were
recently up in the $7-8 range, though they have followed the rest of the
NASDAQ in the last month and dropped to around $4. (Its been a tedious
year, but my portfolio is still *way* up overall for the year).
-James Rogers
jamesr@best.com
This archive was generated by hypermail 2.1.5 : Fri Nov 01 2002 - 15:32:31 MST